Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povor
- Company
- Incyte Corp. (INCY)
- Drug
- povorcitinib
- Indication
- NonSegmental Vitiligo
Other upcoming events for INCY
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Parti
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povor
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Pa
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of A
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.